 This is a medical research study to evaluate the safety and effectiveness of an antibody called infliximab Remicade in the treatment of children with Crohns disease. In this study, subjects will receive multiple doses of infliximab over 62 weeks. The goal of the study is to ensure that the medication is safe and effective in children when it is given for an extended period of time. All subjects will receive an induction regimen of 5 mgkg infliximab at Weeks 0, 2, and 6. Subjects will then receive either 5 or 10 mgkg infliximab either every 8 or 12 weeks for up to 46 weeks followed by an open label extension for up to three additional years. 